# US 2025/0049715 A1 · Membrane Encapsulated Nanoparticles and Method of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049715 A1
- Document ID: US20250049715A1
- Status: Published application
- Kind: A1
- Application number: 18/814,200
- Filed: 2024-08-23
- Published: 2025-02-13
- Earliest claimed: 2011-06-02
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Liangfang Zhang; Che-Ming (Jack) Hu; Ronnie Hongbo Fang; Jonathan Copp
- Web page: https://patentgrep.com/patent/US20250049715A1

## CPC

- A61K 9/148: {with compounds of unknown constitution, e.g. material from plants or animals (with oils, fats, waxes, shellac A61K9/145)}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 39/085: Staphylococcus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the inventive nanoparticles are also provided. Further provided are immunogenic compositions comprising the inventive nanoparticles, and methods of using the inventive immunogenic compositions for eliciting an immune response, and for treating or preventing diseases or condition, such as neoplasm or cancer, or disease or conditions associated with cell membrane inserting toxin. Vaccines comprising the immunogenic composition comprising the nanoparticles are also provided.

## Claims

### Claim 1

A nanoparticle comprising:
a) an inner core comprising a non-cellular material; and
b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein the inner core comprises a biocompatible or a synthetic material selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.

### Claim 3 (depends on 1)

The nanoparticle of claim 1, wherein the cellular membrane is derived from a blood cell, a tumor cell, a cancer cell, an immune cell, a stem cell, an endothelial cell, an exosome, a secretory vesicle or a synaptic vesicle.

### Claim 4 (depends on 3)

The nanoparticle of claim 3, wherein the cellular membrane comprises a plasma membrane derived from a red blood cell.

### Claim 5 (depends on 1)

The nanoparticle of claim 1, which further comprises a releasable cargo.

### Claim 6 (depends on 5)

The nanoparticle of claim 5, wherein the releasable cargo is a therapeutic agent, a prophylactic agent, a diagnostic or marker agent, a prognostic agent, or a combination thereof.

### Claim 7 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle has a half-life in blood circulation in vivo for at least about 2-5 times of the half-life of a PEG-coated, comparable nanoparticle, or has a half-life in blood circulation in vivo for at least about 5 to about 40 hours.

### Claim 8 (depends on 1)

A medicament delivery system, which comprises an effective amount of the nanoparticle of claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising an effective amount of the nanoparticle of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 10 (depends on 1)

A method for treating or preventing a disease or condition in a subject in need comprising administering to said subject an effective amount of the nanoparticle of claim 1.

### Claim 11

A process for making a nanoparticle comprising:
a) combining an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus; and
b) exerting exogenous energy on the combination to form a nanoparticle comprising said inner core and said outer surface.

### Claim 12

A neoplasm specific immunogenic composition comprising an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a neoplasm cell.

### Claim 13 (depends on 12)

A vaccine comprising the neoplasm specific immunogenic composition of claim 12.

### Claim 14 (depends on 12)

A method for treating or preventing a neoplasm in a subject in need comprising administering to said subject an effective amount of the neoplasm specific immunogenic composition of claim 12.

### Claim 15

A pharmaceutical composition for treating or preventing a disease or condition associated with a cell membrane inserting toxin, wherein said pharmaceutical composition comprises an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material and an outer surface comprising a cellular or plasma membrane derived from a target cell.

### Claim 16 (depends on 15)

A method for treating or preventing a disease or condition associated with a cell membrane inserting toxin in a subject in need comprising administering to said subject an effective amount of the pharmaceutical composition of claim 15.

### Claim 17

An immunogenic composition comprising an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a cell and a cell membrane inserting toxin.

### Claim 18 (depends on 17)

A vaccine comprising the immunogenic composition of claim 17.

### Claim 19 (depends on 17)

A method for eliciting an immune response to a cell membrane inserting toxin in a subject comprising administering to said subject an effective amount of the immunogenic composition of claim 17.

### Claim 20 (depends on 18)

A method for protecting a subject against a cell membrane inserting toxin comprising administering to said subject an effective amount of the vaccine of claim 18.

### Claim 21 (depends on 13)

A method for treating or preventing a neoplasm in a subject in need comprising administering to said subject an effective amount of the vaccine of claim 13.
